Noninvasive Tests for Liver Fibrosis

ABSTRACT

The field of noninvasive markers for the assessment of hepatic fibrosis has seen tremendous growth in the last two decades. Surrogate markers are gradually being substituted for biomarkers that reflect the complex balance between synthesis and degradation of the extracellular matrix. Coupled with these promising tests are artificial intelligence networks devised by sophisticated statistical instruments that incorporate a battery of laboratory tests and biomarkers with imaging modalities. Recently, gene identification and protein analysis have shown promise in identifying selected patients with mild or advanced fibrosis. Despite such progress, an important limitation of these tests is the frequent inability to detect mild fibrosis although patients at the end of the histological spectrum (i.e., advanced fibrosis or cirrhosis) are readily identified. With time, it is anticipated a combination of serological and radiological tests together with genetic and proteomic investigations will provide accurate assessment of fibrosis in a cost-effective and timely manner.

KEYWORDS

Noninvasive tests - fibrosis - serological markers - radiological markers

REFERENCES

• 1 Cholongitas E, Senzolo M, Standish R et al.. A systematic review of the quality of liver biopsy specimens.  Am J Clin Pathol. 2006;  125 710-721
• 2 Regev A, Berho M, Jeffers L J et al.. Sampling errors and intraobserver variation in liver biopsy in patients with chronic hepatitis C infection.  Am J Gastroenterol. 2002;  97 2614-2618
• 3 Kelleher T B, Afdhal N. Noninvasive assessment of liver fibrosis.  Clin Liver Dis. 2005;  9 667-683
• 4 Friedman S L, Bansal M B. Reversal of hepatic fibrosis: fact or fantasy.  Hepatology. 2006;  43 S82-S88
• 5 Tsukada S, Parsons C J, Rippe R A. Mechanisms of liver fibrosis.  Clin Chim Acta. 2006;  364 33-60
• 6 Wai C T, Greenson J K, Fontana R J et al.. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.  Hepatology. 2003;  38 518-526
• 7 Adinolfi L E, Giordano M G, Andreana A et al.. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis.  Br J Haematol. 2001;  113 590-595
• 8 Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells.  Hepatology. 1985;  5 367-375
• 9 Lackner C, Struber G, Liegl B et al.. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.  Hepatology. 2005;  41 1376-1382
• 10 Sebastiani G, Vario A, Guido M et al.. Stepwise combination algorithm of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.  J Hepatol. 2006;  44 686-693
• 11 Le Calvez S, Thabut D, Messous D et al.. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C.  Hepatology. 2004;  39 862-863
• 12 Forns X, Ampurdanes S, Llovet J M et al.. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model.  Hepatology. 2002;  36 986-992
• 13 Macias J, Giron-Gonzalez J A, Gonsalez-Serrano M et al.. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes.  Gut. 2006;  55 409-414
• 14 Imbert-Bismut F, Ratziu V, Pieroni L et al.. Biochemical markers of liver fibrosis on patients with hepatitis C virus infection: a prospective study.  Lancet. 2001;  357 1069-1075
• 15 Myers R P, Tainturier M-H, Ratziu V et al.. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.  J Hepatol. 2003;  39 222-230
• 16 Rossi E, Adams L A, Prins A et al.. Validation of the Fibrotest Biochemical Markers Score in assessing liver fibrosis in hepatitis C patients.  Clin Chem. 2003;  49 450-454
• 17 Poynard T, Zoulim F, Ratziu V et al.. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.  Am J Gastroenterol. 2005;  100 1970-1980
• 18 Thuluvath P J, Krok K L. Noninvasive markers of liver fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time?.  Am J Gastroenterol. 2005;  100 1981-1983
• 19 Shiffman M L, Hofmann C M, Contos M J et al.. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology. 1999;  117 1164-1172
• 20 Naveau S, Raynard B, Ratziu V et al.. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.  Clin Gastroenterol Hepatol. 2005;  3 167-174
• 21 Ratziu V, Massard J, Charlotte F et al.. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006;6:6 Available at: http://www.biomedcentral.com/1471-230X/6/6 Accessed May 21, 2006
• 22 Poynard T, McHutchinson J, Manns M, Myers R P, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.  Hepatology. 2003;  38 481-492
• 23 Imbert-Bismut F, Messous D, Thibaut V et al.. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors.  Clin Chem Lab Med. 2004;  42 323-333
• 24 Thabut D, Trabut J B, Massard J et al.. Non-invasive diagnosis of large esophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study.  Liver Int. 2006;  26 271-278
• 25 Nandi A, Estess P, Siegelman M H. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44.  J Biol Chem. 2000;  275 14939-14948
• 26 Wong V S, Hughes V, Trull A et al.. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C infection.  J Viral Hepat. 1998;  5 187-192
• 27 McHutchison J G, Blatt L M, de Medina M et al.. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group.  J Gastroenterol Hepatol. 2000;  15 945-951
• 28 Halfon P, Bourliere M, Peneranda G et al.. Accuracy of hyaluronic acid for predicting liver fibrosis stages in patients with hepatitis C. Comp Hepatol 2005;4:6 Available at: http://www.comparative-hepatology.com/content/4/1/6 Accessed April 10, 2006
• 29 Fraser J R, Gibson P R. Mechanisms by which food intake elevated circulating levels of hyaluronan in humans.  J Intern Med. 2005;  258 460-466
• 30 Vrochides D, Papanikalaou V, Pertoft H, Antoniades A A, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration.  Hepatology. 1996;  23 1650-1655
• 31 Montazeri G, Estakhri A, Mohamednejad M et al.. Serum hyaluronates as a non-invasive marker of hepatic fibrosis and inflammation in HbeAg-negative chronic hepatitis B.  BMC Gastroenterol. 2005;  5 32
• 32 Poynard T, Imbert-Bismut F, Ratziu V et al.. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial.  J Viral Hepat. 2002;  9 128-133
• 33 Lebensztejn D M, Kaczmarski M, Sobaniec-Lotowska M et al.. Serum laminin-2 and hyaluronan predict severe liver fibrosis in children with hepatitis B.  Hepatology. 2004;  39 868-869
• 34 Zeng M D, Lu L G, Mao Y M et al.. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a non-invasive model.  Hepatology. 2005;  42 1437-1445
• 35 Suzuki A, Anjulo P, Lymp J et al.. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease.  Liver Int. 2005;  25 779-786
• 36 Angulo P, Keach J C, Batts K P, Lindor K D. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.  Hepatology. 1999;  30 1356-1362
• 37 Walsh K M, Fletcher A, MacSween R N, Morris A J. Comparison of assays for N-amino terminal propeptide of type III procollagen in chronic hepatitis C by using receiver operating characteristics.  Eur J Gastroenterol Hepatol. 1999;  11 827-831
• 38 Guechot J, Laudat A, Loria A et al.. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis.  Clin Chem. 1996;  42 558-563
• 39 Leonardi S, La Spina M, La Rosa M, Schiliro G. Prolylhydroxylase and procollagen type III in long-term survivors of acute lymphoblastic leukemia (ALL): a biochemical approach to HCV-related liver disease.  Med Pediatr Oncol. 2003;  41 17-20
• 40 Chalmers R J, Kirby B, Smith A et al.. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.  Br J Dermatol. 2005;  152 444-450
• 41 Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10 year follow-up.  Br J Dermatol. 2001;  144 100-103
• 42 Serejo F, Costa A, Gouveia Olivera A et al.. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.  Dig Dis Sci. 2001;  46 1684-1689
• 43 Ponomarenko Y, Anna Leo M, Kroll W, Lieber C S. Effects of alcohol consumption on eight circulating markers of liver fibrosis.  Alcohol Alcohol. 2002;  37 252-255
• 44 Iredale J P. Hepatic stellate cell behaviour during resolution of liver injury.  Semin Liver Dis. 2001;  21 427-436
• 45 Murphy F R, Issa R, Zhou X et al.. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis.  J Biol Chem. 2002;  277 11069-11076
• 46 Walsh K M, Timms P, Campbell S et al.. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as non-invasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.  Dig Dis Sci. 1999;  44 624-630
• 47 Boeker K H, Haberkorn C I, Michels D et al.. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.  Clin Chim Acta. 2002;  316 71-81
• 48 Leroy V, Monier F, Bottari S et al.. Circulating matrix metalloproteinases 1,2,9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.  Am J Gastroenterol. 2004;  99 271-279
• 49 Lebensztejn D M, Sobaniec-Lotowska M E, Bauer M et al.. Serum fibrosis markers as predictors of an anti-fibrotic effect of interferon alfa in children with chronic hepatitis B.  Eur J Gastroenterol Hepatol. 2005;  17 843-848
• 50 Johansen J S, Christoffersen P, Moller S et al.. Serum YKL-40 is increased in patients with hepatic fibrosis.  J Hepatol. 2000;  32 911-920
• 51 Bigg H F, Wait R, Rowan A D, Cawston T E. The mammalian chitinase-like lectin, YKL-40, binds specifically to type I collagen and modulates the rate of type I collagen fibril formation.  J Biol Chem. 2006;  281 21082-21095
• 52 Saitou Y, Shiraki K, Yamanaka Y et al.. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.  World J Gastroenterol. 2005;  11 476-481
• 53 Nojgaard C, Johansen J S, Christensen E et al.. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.  J Hepatol. 2003;  39 179-186
• 54 Nunes D, Fleming C, Offner G et al.. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease.  J Acquir Immune Defic Syndr. 2005;  40 538-544
• 55 Johansen J S, Jensen B V, Roslind A et al.. Serum YKL-40, a new prognostic biomarker in cancer patients?.  Cancer Epidemiol Biomarkers Prev. 2006;  15 194-202
• 56 Nordenbaek C, Johansen J S, Haldberg P et al.. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.  Scand J Rheumatol. 2005;  34 293-297
• 57 Koutroubakis I E, Petinaki E, Dimoulios P et al.. Increased serum levels of YKL-40 in patients with inflammatory bowel disease.  Int J Colorectal Dis. 2003;  18 254-259
• 58 Rathcke C N, Johansen J S, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.  Inflamm Res. 2006;  55 53-59
• 59 Patel K, Gordon S C, Jacobson I et al.. Evaluation of a panel of non-invasive serum markers to differentiate mild from advanced liver fibrosis in chronic hepatitis C patients.  J Hepatol. 2004;  41 935-942
• 60 Poordad F F. FIBROSPECT II: a potential noninvasive test to assess hepatic fibrosis.  Expert Rev Mol Diagn. 2004;  4 593-597
• 61 Rosenberg W M, Voelker M, Thiel R et al.. Serum markers detect the presence of liver fibrosis: a cohort study.  Gastroenterology. 2004;  127 1704-1713
• 62 Bissell D M. Assessing fibrosis without a liver biopsy: are we there yet?.  Gastroenterology. 2004;  127 1847-1849
• 63 Kelleher T B, Mehta S H, Bhaskar R M et al.. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index.  J Hepatol. 2005;  43 78-84
• 64 Adams L A, Bulsara M, Rossi E et al.. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.  Clin Chem. 2005;  51 1867-1873
• 65 Cales P, Oberti F, Michalak S et al.. A novel panel of blood markers to assess the degree of liver fibrosis.  Hepatology. 2005;  42 1373-1381
• 66 Benlloch S, Berenguer M, Prieto M et al.. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index.  Liver Transpl. 2005;  11 456-462
• 67 Lee V S. Science to practice: Can MR imaging replace liver biopsy for the diagnosis of early fibrosis?.  Radiology. 2006;  239 309-310
• 68 Colletta C, Smirne C, Fabris C et al.. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.  Hepatology. 2005;  42 838-845
• 69 Corpechot C, El Naggar A, Poujol-Robert A et al.. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC.  Hepatology. 2006;  43 1118-1124
• 70 Masaki N, Imamura M, Kikuchi Y, Oka S. Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C and human immunodeficiency virus.  Hepatol Res. 2006;  35 135-139
• 71 Laharie D, Zerbib F, Adhoute X et al.. Diagnosis of liver fibrosis by transient elastography (Fibroscan) and non-invasive methods in Crohn's disease patients treated with methotrexate.  Aliment Pharmacol Ther. 2006;  23 1621-1628
• 72 Castera L, Vergniol J, Foucher J et al.. Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C.  Gastroenterology. 2005;  128 343-350
• 73 McClain C J, Cohen D A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis.  Hepatology. 1989;  9 349-351
• 74 McClain C, Barve S, Joshi-Barve S et al.. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease.  Alcohol Clin Exp Res. 2005;  29 180S-188S
• 75 Kanzler S, Baumann M, Schirmacher P et al.. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.  J Viral Hepat. 2001;  8 430-437
• 76 Ben-Ari Z, Pappo O, Druzd T et al.. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation.  Cytokine. 2004;  27 7-14
• 77 Akpolat N, Yahsi S, Godekmerdan A et al.. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B.  World J Gastroenterol. 2005;  11 3260-3263
• 78 Dev A, Patel K, Conrad A et al.. Relationship of smoking and fibrosis in patients with chronic hepatitis C.  Clin Gastroenterol Hepatol. 2006;  4 797-801
• 79 Musso G, Gambino R, Biroli G et al.. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2005;  100 2438-2446
• 80 Musso G, Gambino R, Durazzo M et al.. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease.  Hepatology. 2005;  42 1175-1183
• 81 Hui J M, Hodge A, Farrell G C et al.. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40 46-54
• 82 Bahcecioglu I H, Yalniz M, Ataseven H et al.. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.  Hepatogastroenterology. 2005;  52 1549-1553
• 83 Day C P. Genetic studies to identify hepatic fibrosis genes and SNP's in human populations.  Methods Mol Med. 2005;  117 315-331
• 84 Patel K, Norris S, Lebeck L et al.. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C.  Hepatology. 2006;  43 241-249
• 85 Bataller R, North K E, Brenner D A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal.  Hepatology. 2003;  37 493-503
• 86 Huang H, Shiffman M L, Cheung R C et al.. Identification of two gene variants associated with risk of advanced fibrosis in patients with hepatitis C.  Gastroenterology. 2006;  130 1679-1687
• 87 Blanton R E, Salam E A, Ehsan A, King C H, Goddard K A. Schistosomal hepatic fibrosis and the interferon gamma receptor: a linkage analysis using single-nucleotide polymorphic markers.  Eur J Hum Genet. 2005;  13 660-668
• 88 Kamal S, Turner B, He Q et al.. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis.  Hepatology. 2006;  43 771-779
• 89 Poon T C, Hui A Y, Chan H L et al.. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting.  Clin Chem. 2005;  51 328-335
• 90 Callewaert N, Van Vlierbeghe H, Van Hecke A et al.. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics.  Nat Med. 2004;  10 429-434
• 91 Ishibashi K, Nishikawa A, Hayashi N et al.. N-acetylglucosaminyltransferase III in human serum, and liver and hepatoma tissues: increased activity in liver cirrhosis and hepatoma patients.  Clin Chim Acta. 1989;  185 325-332
• 92 Kuroda Y, Nakata M, Makino A et al.. Structural studies on IgG oligosaccharides of patients with primary Sjogren's syndrome.  Glycoconj J. 2002;  19 23-31
• 93 Pagliaro L, Rinaldi F, Craxi A et al.. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis: a prospective, randomized trial.  Dig Dis Sci. 1983;  28 39-43
• 94 Ratziu V, Charlotte F, Heurtier A et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease.  Gastroenterology. 2005;  128 1898-1906
• 95 Poniachik J, Bernstein D E, Reddy K R et al.. The role of laparoscopy in the diagnosis of cirrhosis.  Gastrointest Endosc. 1996;  43 568-571
• 96 Helmreich-Becker I, Schirmacher P, Denzer U et al.. Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease.  Endoscopy. 2003;  35 55-60